The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0

EJNMMI Research

Table 1 Patient characteristics, overall PSMA-RADS scores, and correlative data (n = 15)

No	Age (y)	Biopsy ISUP	Pre-RP PSA	Clinical stage		Risk-group^a	RP ISUP	EPE	SVI	Lymph nodes dissected/positive	Tracer	Overall PSMA-RADS	1st PSA (ng/ml)	2nd PSA (ng/ml)	Correlative modalities
1	62	2	5.5	T1c		1	2	n	n	7/0	18F-PSMA-1007	3B	0.04	0.07	MRI, CT
2	69	2	5.1		T2b	1	2	y	y	9/0	68 Ga-PSMA-11	3B	0	0	Rib cage X-ray
3	76	3	15		T1c	2	3	y	y	13/0	68 Ga-PSMA-11	4	1.4	n/a^b	MRI, follow-up PSMA PET/CT
4	74	3	5		T1c	2	3	y	n	8/0	68 Ga-PSMA-11	3B	0.09	0.09	None
5	64	2	4.5		T1c	3	2	n	n	12/0	68 Ga-PSMA-11	3B	0.09	0.09	Follow-up PSMA PET/CT
6	73	3	16		T2a	2	2	Y	n	9/0	18F-PSMA-1007	3B	0	0	None
7	57	1	10.5		T2a	1	2	n	n	20/0	18F-PSMA-1007	3B	0	0	MRI
8	56	2	12.13		T2b	2	2	y	n	21/0	68 Ga-PSMA-11	3B	0	0	MRI^c
9	69	3	10		T2b	2	3	y	n	19/0	68 Ga-PSMA-11	3B	0.54	0.81	MRI, follow-up PSMA PET/CT
10	46	2	13		T1c	2	2	y	n	21/0	68 Ga-PSMA-11	3B	0	0	Histopathology
11	70	2	6.3		T1c	1	3	y	n	14/0	68 Ga-PSMA-11	3B	0	0	None
12	51	3	25		T3	3	3	y	y	14/1	68 Ga-PSMA-11	3B	2.9	4.1	MRI, follow-up PSMA PET/CT
13	72	4	6.5		T1c	3	4	y	n	7/1	68 Ga-PSMA-11	5	3	22	Follow-up PSMA PET/CT
14	74	3	9		T1c	2	3	n	n	14/0	68 Ga-PSMA-11	3B	0	0	None
15	63	2	7		T1c	1	3	y	n	17/0	68 Ga-PSMA-11	3B	0	n/a	Follow-up PSMA PET/CT

RP radical prostatectomy, ISUP International Society of Urological Pathology, EPE extraprostatic extension, SVI seminal vesicle invasion, MRI magnetic resonance imaging
^aNCCN risk group: 1 = favorable intermediate; 2 = unfavorable intermediate; 3 = high
^bPatient already started on systemic therapy with PSA reduction
^cMRI findings inconclusive. However, a CT scan performed 10 years earlier showed the same finding, supporting a nonprostatic etiology